join the webinar:

Society is in the midst of Medical 4.0 — a slate of technologies and new disciplines described as the fourth industrial revolution. This transformation promises to radically address some of the most challenging medical and healthcare related challenges faced by humankind.

But, for many people living everyday with chronic brain conditions, it cannot come fast enough.

Renowned clinician and neuroscientist, Professor Patrick Kwan, is working to change lives for people with epilepsy and other neurological conditions so they have the best possible outcomes.

He will speak on bringing together clinicians, researchers, medical engineers, data scientists and people with lived experience as the best strategy to develop breakthroughs to meet important and challenging needs. It’s a process akin to a harmonic symphony of teamwork, rather than an impersonal assembly line full of parts. And it's all about not accepting the status quo.

Patrick will address the extraordinary range and depth of the creativity, innovation, collaboration and collective synthesis underpinning this seismic shift in medical research.

From personalising treatment for an individual using AI, to reprogramming stem cells to capture the essence of what makes each of us unique, and wearable biosensors to put diagnosis in your hands, this tour of medtech and out-of-the-box scientific inquiry, will culminate in his vision for the future of epilepsy research.

SPEAKER BIO

Patrick Kwan is a Professor of Neurology in the Department of Neuroscience within the School of Translational Medicine at Monash University, and Consultant Neurologist and Director of the Epilepsy Unit at Alfred Health. He is Co-Director of the Monash Institute of Medical Engineering (MIME).
He is a medical specialist in neurology and an international authority in epileptology. His research portfolio encompasses both applied basic science and clinical aspects to improve the treatment outcomes of epilepsy. His research is focused on understanding the long-term treatment outcomes, mechanisms of epileptogenesis and drug resistance, and genomics and pharmacogenomics of epilepsy. He has a particular interest in harnessing technologies to solve clinical problems, including machine learning and stem cell approaches for personalised medicine, and novel assays and biosensors for point-of-care in vitro diagnosis.

DONATE TO RESEARCH AT MONASH TRANSLATIONAL MEDICINE

Find out more about donating to Monash Translational Medicine research projects here.
Or contact
Ms Carrie Keller
Deputy Director, Development (Clinical and Biomedicine Research)
Office of the President and Vice-Chancellor
E: carrie.keller@monash.edu
M: 0428 873 633